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Adding the angiogenesis inhibitor bevacizumab to initial 
standard chemotherapy followed by bevacizumab alone as 
maintenance therapy prolongs progression-free survival 
(PFS) time significantly but modestly in women with 
advanced epithelial ovarian cancer. This finding has been 
reported consistently by two phase III trials, GOG-218 
and ICON 7. At present, overall survival (OS) data are 
immature. Therefore, no recommendation can be made 
yet how to best incorporate bevacizumab in the front-line 
treatment of advanced ovarian cancer. 
Members of the gynecological cancer working group of 
the Swiss Group for Clinical Cancer Research (SAKK) and 
other specialists have discussed the latest findings with 
bevacizumab in ovarian cancer and their consequences for 
clinical practice.
Ovarian cancer is the seventh most frequent cancer in 
women worldwide (1). Its incidence rates are highest in 
the western world, where it is the leading cause of death 
from gynecological malignancies (2, 3). 
Patients with stage III and IV ovarian cancer require a 
combined approach of surgery and chemotherapy. Primary 
debulking surgery plays a key role and the final outcome 
is highly dependent on the results achieved with the ini-
tial surgery: a residual tumor of >1 cm was found to be as-
sociated with a median overall survival of 12–16 months, 
while a longer median overall survival has been reported 
in patients with no macroscopic residual disease (4). The 
ultimate goal of surgery is cytoreduction to microscopic 
disease, the term optimal cytoreduction being reserved for 
those cases with no macroscopic residual disease. 
The standard first-line chemotherapy for advanced ovar-
ian cancer usually contains a taxane and a platinum agent 
for six cycles (5-8). The response rate for this treatment is 
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approximately 75%. However, 65% of these patients will 
develop tumor progression in the first three years after di-
agnosis. Over the past ten years, the only improvement in 
overall survival has been reported with the introduction of 
a dose dense schedule of paclitaxel (9) or by the use of lo-
cal ip treatment in selected patients (10); the addition of a 
third cytotoxic to standard chemotherapy has not showed 
any significant advantage over the established first-line 
chemotherapy (11, 12).
Identification of new targets
Better knowledge of the molecular biology has prompted 
new treatment approaches, such as inhibition of angio-
genesis. In ovarian cancer, the vascular endothelial growth 
factor (VEGF) is overexpressed and is associated with asci-
tes formation and malignant progression (13, 14). In pre-
clinical studies with anti-VEGF therapy, delayed tumor 
progression, resolution of malignant effusions, and syn-
ergy with cytotoxic agents have been demonstrated (15).
Bevacizumab is a recombinant, humanized antibody to 
VEGF, which inhibits tumor angiogenesis and which has 
shown promising activity in recurrent ovarian cancer as a 
single agent and in combination with chemotherapy (15-
17). Further angiogenesis inhibitors are investigated in 
clinical trials (phase I and II) in this disease e.g. cediranib, 
pazopanib and AMG 386.
To understand the role of bevacizumab in the initial treat-
ment of advanced ovarian cancer, two groups of academic 
investigators, the Gynecologic Oncology Group (GOG) 
and the Gynecologic Cancer Intergroup (GCIG), conduct-
ed separate phase III trials with a total accrual of 3,401 
patients. Both trials, GOG-218 and ICON 7, assessed the 
effect of the addition of bevacizumab to standard therapy 
and the effect of maintenance treatment with single agent 
bevacizumab (18, 19).
GOG-218
This double-blind, placebo-controlled study included 
1,873 women with newly diagnosed, epithelial ovarian 
cancer after debulking surgery (stage III optimal (mac-
roscopic residual disease ≤ 1 cm) or suboptimal (>1 cm) 
or stage IV). Patients were randomly assigned to one of 
three treatment groups: six cycles of chemotherapy (car-
boplatin/paclitaxel every 3 weeks) and concurrent placebo 
followed by placebo maintenance (arm I), or six cycles 
of chemotherapy and concurrent bevacizumab (15 mg/
kg every 3 weeks) followed by placebo maintenance (arm 
II), or bevacizumab maintenance (arm III) given for up to 
15 months (16 cycles), intolerable toxicity or until pro-
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gression. Disease progression was 
defined based on RECIST, global 
clinical deterioration, or CA-125.
After a median follow-up of 17.4 months, the primary 
analysis showed that the median PFS was significant-
ly higher in arm III (14.1 months) than in arm I (10.3 
months) (Fig. 1). This translated into a 28% reduction 
in the risk of progression (median gain of 3.8 months) for 
concurrent and additional maintenance treatment with 
bevacizumab (arm III). Compared to chemotherapy alone, 
the hazard ratio of tumor progression for concurrent and 
maintenance bevacizumab was 0.717 (95% CI, 0.625–
0.824; P<0.0001). There was no significant difference in 
median PFS between arms II (11.2 month) and I.
A retrospective analysis, censoring for progression events 
that were solely based on CA-125 elevation, showed 
that PFS was 6 months longer (18 versus 12 months, 
P <0.0001). The hazard ratio for progression for concur-
rent bevacizumab followed by placebo maintenance was 
0.908 (95% CI, 0.795–1.04; P = 0.16), i.e. the PFS with 
concurrent bevacizumab (arm II) was not statistically dif-
ferent from the one with chemotherapy alone (arm I).
The OS analysis conducted at the time of the final PFS 
analysis did not show any conclusive differences between 
the three treatments. However, data were not sufficiently 
mature with roughly 20% of events at the time of the 
first OS analysis. Mature PFS and OS data are expected in 
2012. After tumor progression, treatment was unblinded 
and cross-over to bevacizumab was possible. If this will 
confound long-term data evaluation will be seen in the 
future. 
The type and severity of adverse events were similar to 
those reported with bevacizumab in combination with 
chemotherapy in the treatment of other metastatic solid 
tumors (Table 1). There was no increased risk for gastroin-
testinal perforation and fistula, with rates of less than 3% 
in all treatment groups.
ICON 7
This open-label study included 1,528 women with newly 
diagnosed epithelial ovarian cancer. The majority of pa-
tients had advanced stage ovarian cancer, but also patients 
with earlier-stage could be included, representing about 
10% of the population in each arm. The patients were 
randomized to receive either six cycles of chemotherapy 
alone (carboplatin/paclitaxel every 3 weeks) or with con-
current bevacizumab at 7.5 mg/kg every 3 weeks followed 
by bevacizumab alone for a further 12 cycles up to 12 
months. 
Median follow-up at the time of analysis was 19.4 months. 
Bevacizumab in addition to chemotherapy and continued 
up to 12 months improved the PFS from a median of 17.3 
months to 19.0 months with a hazard ratio of 0.81 (95% 
CI, 0.70–0.94; P=0.0041, academic analysis) (Fig. 2). 
Mature data to assess OS and mature PFS data are expect-
ed in 2012; at the time of the first analysis only 16% of 
OS events had occurred. The treatment was well tolerated 
with no new toxicities reported (Table 1). 
GOG-218 and ICON7: Consistent findings from well 
designed studies but open questions remain
GOG-218 and ICON 7 are two well-designed random-
ized trials conducted at high quality standards and have 
enrolled more than 3,300 women with advanced ovarian 
cancer. There are some differences between the two tri-
als: the most relevant are the design (GOG-0218: double 
blind; ICON 7: open-label), the dosage of bevacizumab 
(15 mg/kg; 7.5 mg/kg), the duration of maintenance 
therapy (15 months; 12 months), the patient population 
(stage III and IV; high-risk early FIGO stage I, IIa as well 
as stage III and IV), percent of patients with suboptimal 
surgery (39%; vs 26%). 
Fig. 1 GOG-218: 
Academic analysis
of PFS
Fig. 2 ICON-7: Academic analysis of PFS
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These two studies are so far the only large, randomized 
phase III trials which have demonstrated an improved 
PFS with an anti-angiogenic agent in combination with 
standard chemotherapy in the initial treatment of ovarian 
cancer. 
Several questions still need to be answered. Should beva-
cizumab be used during the initial part of the treatment 
as well as in the subsequent maintenance phase? What 
is the most appropriate dosage and duration of treatment 
for bevacizumab? Would bevacizumab also add benefit to 
the weekly paclitaxel regimen, which is not yet regarded 
as standard? It cannot be concluded from these findings 
whether inhibition of VEGF may have a greater impact on 
tumor regrowth in the management of recurrent disease 
than in the first-line treatment. Mature data on OS and 
quality of life are awaited.
What are the consequences for clinical practice?
The proof of principle of the effect of anti-angiogenic ther-
apy in ovarian cancer has been confirmed by both GOG 
218 and ICON 7. However, additional data from those 
studies and others are needed to clarify how to best in-
corporate bevacizumab into the treatment of ovarian can-
cer. Open questions have been addressed by Roche as well 
as international gynecological and oncological societies, 
and both have committed themselves to answer these and 
other questions in future clinical trials. Until these trials 
reports are available bevacizumab cannot be considered as 
initial standard treatment even though the two trials sug-
gest that incorporation of bevacizumab in the control arm 
of a randomized trial could be a valid option. 
It is not possible to define a patient population who could 
clearly benefit from bevacizumab. The decision to treat a 
woman with ovarian cancer with bevacizumab can only be 
made on an individual basis. By contrast, the patients who 
should not be treated with bevacizumab because of safety 
concerns include those with:
• uncontrolled hypertension
• a history of thrombosis in the last 6 months or a ten-
dency to develop thrombosis
• symptomatic central nervous system metastases
• recent hemoptysis 
• significant cardiovascular disease or cardiac failure
• bleeding disorders
• eligibility for secondary surgery (due to wound-healing 
complications induced by bevacizumab (if administered 
less than 4 weeks after surgery))
• extensive bowel involvement
• multiple stenosis
• subileus.
Conclusions
The GOG-218 and ICON 7 studies are examples of high-
quality, clinical investigations with international collab-
oration. ICON 7 validates and extends the observations 
from GOG-218, confirming that VEGF is an important 
Select adverse events, % 
(grade when limited)
GOG-0218
CP
(n=601)
GOG-0218
CP + B15
(n=607)
GOG-0218
CP + B15® 
B15 (n=608)
ICON7
CP+(n=753)
ICON7
CP + B7.5®
B7.5 (n=745)
GI Events (Perforation/fistula/necrosis/leak (grade ≥2)) 1.2 2.8 2.6 – –
Fistula/abscess (grade ≥3) – – – 0.9 0.8
GI perforation (grade ≥3) – – – 0.4 1.3
Hypertension (grade ≥2) 7.2 16.5 22.9 2.1 18.3
Proteinuria (grade ≥3) 0.7 0.7 1.6 0.1 0.5
Pain (grade ≥2) 41.7 41.5 47.5 NR NR
Neutropenia (grade ≥4) 57.7 63.3 63.3  15.1* 16.5*
Febrile neutropenia (all grades) 3.5 4.9 4.3 2.0 2.8
Venous thromboembolic event (all grades) 5.8 5.3 6.7 4.1 6.7
Arterial thromboembolic event (all grades) 0.8 0.7 0.7 1.5 3.6
CNS bleeding (grade ≥3) 0 0 0.3 NR NR
Non-CNS bleeding (grade ≥3) 0.8 1.3 2.1 0.3 1.2
RPLS 0 0.2 0.2 0 0
  *Neutropenia Grade  ≥ 3
Table 1: Selected Adverse Events in GOG-0218 and ICON7
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driver in ovarian cancer and that bevacizumab is an ef-
fective agent with acceptable toxicity. However, the im-
provements in PFS observed have yet to be associated with 
improvements in OS or QoL, which are crucial to define 
the clinical benefit of the treatment. 
The most urgent need is to find predictive factors which 
define the patients who will most likely benefit from add-
ing bevacizumab to standard chemotherapy. Thus clini-
cal trials including translational research questions are of 
high priority. At present, bevacizumab in combination 
with carboplatin and paclitaxel cannot be recommended 
as standard first-line therapy; participation in clinical tri-
als is highly recommended. Treatment decisions for pa-
tients who cannot participate in clinical trials must be 
made on an individual basis.
*Swissmedic granted Bevacizumab the orphan drug sta-
tus for the treatment of ovarian cancer (21). Bevacizumab 
for ovarian cancer is not approved in Switzerland (22).
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